I guess the question now becomes do they need to disclose information about the labelling discussions in detail or is that covered by the statement "The Company has worked closely with FDA during the course of the review period and remains in ongoing dialogue with FDA."
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-64
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.020(1.81%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.12 | $4.898M | 4.355M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 596693 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 50805 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
0.020 ( 0.92 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.12 | 1420559 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| MSB (ASX) Chart |